RSS Feeds
Search

Industry news

Orphagen Pharmaceuticals Awarde Federal Grant for Adrenocortical and Prostate Cancer

In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.

Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.

Subscribe now for instant access to the benefits Pharmalicensing Intelligence has to offer. Find out more.

Company details

If you want to find out more about the company visit Orphagen Pharmaceuticals profile.

Related reports

Market Research Reports provided by reports.iptechex.com
Prostate Cancer Drug Discoveries: What the Future Holds
Nov 2009 - 160 pages - $2,265
Jevtana (Cabazitaxel) - Positive Recommendation in the EU for Metastatic Castration-Resistant Prostate Cancer
Mar 2011 - 5 pages - $500
FDA Approves Zytiga (Abiraterone Acetate) for the Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer
May 2011 - 5 pages - $500
Epidemiology: Prostate Cancer – Incidence and prevalence reaches new heights due to testing, risk factors, and an aging population
Mar 2011 - 34 pages - $5,700
Endothelin A Receptor Antagonist (atrasentan) Fails to Demonstrate an Advantage in the Treatment of Advanced Prostate Cancer
May 2011 - 5 pages - $500
Adrenocortical Carcinoma Global Clinical Trials Review, Q4, 2010
Dec 2010 - 33 pages - $1,000
Adrenocortical Carcinoma Adrenal Tumor - Pipeline Review, Q4 2010
Dec 2010 - 24 pages - $500
Adrenocortical Carcinoma Adrenal Tumor Global Clinical Trials Review, Q4, 2010
Dec 2010 - 45 pages - $1,000
Prostate Cancer Therapy Area Pipeline Report
Nov 2010 - 1011 pages - $1,495
Hormone Refractory Prostate Cancer - Pipeline Review, Q4 2010
Nov 2010 - 50 pages - $500
More Related Market Research Reports >>>

Related news

Latest News

Publication of Phase II trial results of NGR-hTNF in liver cancer by the British Journal of Cancer
EISAI ANNOUNCES EXTENSION OF FDA REVIEW OF DRUG APPLICATION FOR INVESTIGATIONAL AGENT ERIBULIN MESYLATE
SciBase successfully achieves clinical study objectives
Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
The Institute of Cancer Research and Horizon Discovery to Collaborate on Genome-wide Synthetic-lethality Screens
Hana Biosciences Reports Second Quarter 2010 Financial Results
Orphagen Pharmaceuticals Awarde Federal Grant for Adrenocortical and Prostate Cancer
TetraLogic Pharmaceuticals COMPLETES $32 Million SERIES C FINANCING
Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety
More news... | RSS Feed...

Most Viewed

Publication of Phase II trial results of NGR-hTNF in liver cancer by the British Journal of Cancer

EISAI ANNOUNCES EXTENSION OF FDA REVIEW OF DRUG APPLICATION FOR INVESTIGATIONAL AGENT ERIBULIN MESYLATE

Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety

SciBase successfully achieves clinical study objectives

TetraLogic Pharmaceuticals COMPLETES $32 Million SERIES C FINANCING

Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment

The Gamida Cell-TEVA Joint Venture Receives FDA Fast Track Designation for StemEx

Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment

Hana Biosciences Reports Second Quarter 2010 Financial Results

The Institute of Cancer Research and Horizon Discovery to Collaborate on Genome-wide Synthetic-lethality Screens

Therapeutic Target

Cardiovascular
Dermatology
Endocrine and Metabolic
Gastroenterology
Genitourinary
Hematology
Immunology and Allergy
Infection
Musculoskeletal
Neurology
Obstetrics and Gynecology
Oncology
Ophthalmology
Psychiatry
Pulmonary

Categories

Deals and Alliances
Development
Financial Results
Financings
Intellectual Property
Regulatory
Press releases
Deals review
Headlines
PR Newswire

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us